Q: If you had to pick one healthcare (realize all are different in makeup) which and briefly why. I am looking for steady and growing dividends and in registered account positioning to a RIF transfer
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: Between GH and INMD which one would you pick for long term growth, and why?
Q: Aurinia Pharma is having a patent concern along with slow sales that’s brought the the stock price down from the 30s to 8 dollars. What do you think about Aurinia and it’s prospects. Is it a buy hold or sell.
Q: My question is regarding selling my XHC and purchasing XLV in my RSP. I have 414 shares of XHC and understand the cost of currency change .I have initiated a position in XLV by selling VIG when it moves beyond 10% of our portfolio and started wondering whether I should consolidate to XLV. Our other healthcare stock is WELL. I would appreciate your comments. Thank you.
Q: Hi 5i, Can I get your take on these 3 companies - current valuation, growth prospects, balance sheet…? I currently hold ILMN. Should I add to ILMN or diversify in the diagnostics/research field by adding TMO or A, and if so, which if the two would you prefer? Growth investor with a long-term time frame.
Thank you, Doris
Thank you, Doris
Q: Now that ENDO has filed for bankruptcy, would GUD still have an opportunity to buy Paladin?
Q: would appreciate your outlook and comments on biotech firm VERTEX.
are their primary products reletively safe and expected to do well?
Ed
are their primary products reletively safe and expected to do well?
Ed
Q: Quarter and future looks bright with new credit facility. View on performance and future prospects?
Q: I own a few hundred shares in Zim largely for the dividend. Today they announced an increase in the quarterly dividend payable Sept 8th to $4.75 yet the shares dropped from over $50. US to under $48. Can you explain this strange behavior. I would have expected it to go the other way.
-
Intuitive Surgical Inc. (ISRG)
-
AbbVie Inc. (ABBV)
-
Bristol-Myers Squibb Company (BMY)
-
Eli Lilly and Company (LLY)
-
Merck & Company Inc. (MRK)
-
Pfizer Inc. (PFE)
Q: what would you suggest for a solid health care position in Canada or the USA? I have UNH. I was looking at HHL but I would like your thoughts on a stock or two. I hope you and the team are enjoying the summer. Thanks Dan.
Q: There has been over $3million insider buying, notably including by the CFO, and the company has redeemed stock consistently over the years.
Is the float getting appreciably smaller? What might be going on here?
John
Is the float getting appreciably smaller? What might be going on here?
John
Q: Good Morning
I have held Vitalhub in my TFSA for some time with no reward for my patience. Although it seems they are making progress, much like WELL they don’t seem to get any recognition from the markets. Would you endorse a switch to DOO, CTS or another name from the Growth Portfolio? Or is more patience warranted given their latest quarterly results?
Thank you
I have held Vitalhub in my TFSA for some time with no reward for my patience. Although it seems they are making progress, much like WELL they don’t seem to get any recognition from the markets. Would you endorse a switch to DOO, CTS or another name from the Growth Portfolio? Or is more patience warranted given their latest quarterly results?
Thank you
Q: I am considering selling XHC and replacing it with HHL in my RSP to add income. Is this a wise move and do you see any other issues with this change? Thx James
Q: May I have your thoughts on ILMN? Analysts appear to be projecting a weak stock price going forward...but the 8% drop on Friday may be more a result of their comments rather than the latest companies financials. Could these Wall Street firms have already shorted the stock prior to their analyst's comments being issued? I believe the latest earnings are negative compared to a year ago but overall I felt the latest quarter financials weren't too bad. Is the short interest high? Are insiders buying? Is the Reddit crowd circling? I'm sitting at a loss but still prepared to hang-in-there.
Thanks,
Jim
Thanks,
Jim
Q: Hi Guys
According to an update i received from Simply Wall St.
12 analysts covering this stock no longer expect the company to break even in the near future.
* They were expected to make a profit of 5.23 million in 2023.
* New consensus forecast suggests the company will make a Loss of 8.75 million in 2023
This doesn't sound very encouraging. What are your views?
Thanks Gord
According to an update i received from Simply Wall St.
12 analysts covering this stock no longer expect the company to break even in the near future.
* They were expected to make a profit of 5.23 million in 2023.
* New consensus forecast suggests the company will make a Loss of 8.75 million in 2023
This doesn't sound very encouraging. What are your views?
Thanks Gord
Q: Please delve into the various components of Knight's quarterly results published this morning including sales, eps, cash position, ebitda, etc.
They still need a big deal to propel them but did this quarter signal an emergence from the previously perpetual doldrums?
Thank you.
They still need a big deal to propel them but did this quarter signal an emergence from the previously perpetual doldrums?
Thank you.
Q: Based on your last comments on June 24th about Sanofi could you please help me understand what's behind the recent drop with the stock recently and is this a good time to buy. Is it now at a "bargain" price what are the financial ratios you like and don't like about this stock? How do you feel about their pipeline of drugs?
Your last comment was SNY: Sanofi is a bit different than the others, being a $130 billion pharma company. The valuation fundamentals look fine, growth expectations are mid-to-low single digits on the top line and it pays a decent dividend. For an 'anchor' type of position, we would not take much issue with a name like this.
Your last comment was SNY: Sanofi is a bit different than the others, being a $130 billion pharma company. The valuation fundamentals look fine, growth expectations are mid-to-low single digits on the top line and it pays a decent dividend. For an 'anchor' type of position, we would not take much issue with a name like this.
Q: Please comment on earnings.
Q: Hello Peter,
The results were not that impressive yet the stock is surging alot.. How does one read into the results as i would not have thought the behavior to be upwards.. Any thoughts please.
The results were not that impressive yet the stock is surging alot.. How does one read into the results as i would not have thought the behavior to be upwards.. Any thoughts please.
Q: What is your take on their quarterly report and prospects going forward. What are your thoughts on the motivation for the bump today? I imagine it could be a combination of things!